Genmab postpones crucial cancer candidate decision following Abbvie exit
![Photo: PR / Genmab](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14303795.ece/ALTERNATES/schema-16_9/doc7m9tayc9v0w1frklg2in.jpg)
The collaboration between Genmab, a Danish biotech company, and US-based Abbvie entails the development of a string of molecules – which was recently cut a little shorter when Abbvie decided to discontinue the shared efforts on one candidate in particular.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Genmab to measure growth hope against bestseller
For subscribers
Genmab beats expectations across the board
For subscribers